Coronavir

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

Retrieved on: 
Thursday, July 22, 2021
Coronaviridae, Zoonoses, Animal diseases, Sarbecovirus, Antiviral drugs, Human coronavirus 229E, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Coronavir, COVID-19, Middle East respiratory syndrome–related coronavirus, Severe acute respiratory syndrome coronavirus

The Phase 1b trial is a double-blind, randomized dose escalation trial in non-hospitalized patients ages 18-65 with mild to moderate COVID-19.

Key Points: 
  • The Phase 1b trial is a double-blind, randomized dose escalation trial in non-hospitalized patients ages 18-65 with mild to moderate COVID-19.
  • Further, in vitro studies have shown that zotatifin has potent antiviral activity across all unique coronavirus subtypes tested, including SARS-CoV-2, SARS-CoV-1, MERS-CoV and CoV-229E.
  • Zotatifin, eFFECTORs inhibitor of eIF4A, has recently completed the dose-escalation portion of a Phase 1/2 trial, and is now progressing into Phase 2a indication-specific expansion cohorts.
  • Neither LWAC nor eFFECTOR gives any assurance that either LWAC or eFFECTOR or the combined company will achieve its expectations.

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

Retrieved on: 
Tuesday, July 20, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Coronaviridae, Zoonoses, Variants of SARS-CoV-2, Antiviral drugs, COVID-19 pandemic in Russia, Severe acute respiratory syndrome coronavirus 2, COVID-19, SARS-CoV-2 Delta variant, Immunome, Coronavir

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing.

Key Points: 
  • Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing.
  • Furthermore, IMM-BCP-01 showed in-vitro activity via non-neutralizing mechanisms, such as complement fixation, which Immunome expects will enable viral clearance.
  • IMM-BCP-01s ability to maintain neutralizing activity against emerging SARS-CoV-2 variants, including the Delta variant, potentially positions our drug candidate as a long-term solution to the changing threat posed by COVID-19.
  • Currently, the delta variant accounts for a majority of coronavirus cases in the United States.

Eurofins Viracor Invests in Innovation with the Launch of Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Testing

Retrieved on: 
Thursday, July 8, 2021
Coronaviridae, Medical specialties, Medicine, Eurofins Scientific, COVID-19 testing, COVID-19, Coronavir, Severe acute respiratory syndrome coronavirus

LEE'S SUMMIT, Mo., July 8, 2021 /PRNewswire/ --As one of the first commercial labs to deliver COVID-19 testing, Eurofins Viracor, Inc. continues to innovate with the launch of Coronavirus SARS-CoV-2 inSIGHT T Cell Immunity testing.

Key Points: 
  • LEE'S SUMMIT, Mo., July 8, 2021 /PRNewswire/ --As one of the first commercial labs to deliver COVID-19 testing, Eurofins Viracor, Inc. continues to innovate with the launch of Coronavirus SARS-CoV-2 inSIGHT T Cell Immunity testing.
  • Viracor's inSIGHT T Cell Immunity test delivers an understanding of a patient's response to viral antigens providing critical insight to aid in treatment decisions.
  • SARS-CoV-2 inSIGHT testing joins a robust menu of COVID-19 testing, including the recently-launched cPASS Coronavirus SARS-CoV-2 Neutralizing Antibody test.
  • Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services.

Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium

Retrieved on: 
Friday, June 18, 2021
Coronaviridae, Sarbecovirus, Health sciences, Medicine, Zoonoses, Antiviral drugs, COVID-19 pandemic in Russia, Coronavir, Severe acute respiratory syndrome, Brilacidin, COVID-19

The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense.

Key Points: 
  • The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense.
  • The presentation on Brilacidin will be part of the Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases Breakout Session.
  • Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.
  • A more complete description of these risk factors is included in the Companys filings with the Securities and Exchange Commission.

Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, May 5, 2021
Antiviral drugs, Medical specialties, Virology, Sarbecovirus, Antigens, HBsAg, Hepatitis B virus, Coronavirus, Coronavir, Severe acute respiratory syndrome coronavirus 2, 7+3, Medicine

This progress reflects our objective to develop a combination regimen that provides a functional cure for people living with HBV.

Key Points: 
  • This progress reflects our objective to develop a combination regimen that provides a functional cure for people living with HBV.
  • We were also gratified to establish an innovative collaboration with X-Chem, Inc. and Proteros biostructures GmbH.
  • The objective of this alliance is to expedite our efforts to discover an effective oral antiviral therapy against coronaviruses including SARS-CoV-2 targeting the main protease.\xe2\x80\x9d\nMr.
  • Efficacy results to date suggest that repeat dosing using the 60 mg dose every 4 weeks resulted in a continuous and robust mean HBsAg decline at week 24 (-1.84 log10 IU/mL, N=7).

airKAVE Portable Air Purifier Now Approved To Combat COVID-19

Retrieved on: 
Thursday, April 15, 2021
Sarbecovirus, Zoonoses, Animal diseases, Infectious diseases, Coronavir, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

b'LOS ANGELES, April 15, 2021 /PRNewswire/ --airKAVE, the world\'s most advanced air purification technology, announced today that the airKAVE Portable passedthe Characterization of Model AH01 Air Purification Device in Deactivation of Aerosolized SARS-COV-2 test (from MRIGlobal).

Key Points: 
  • b'LOS ANGELES, April 15, 2021 /PRNewswire/ --airKAVE, the world\'s most advanced air purification technology, announced today that the airKAVE Portable passedthe Characterization of Model AH01 Air Purification Device in Deactivation of Aerosolized SARS-COV-2 test (from MRIGlobal).
  • The test confirms that airKAVE Portable destroys aerosolized SARS-CoV-2 within a fraction of a second as the air passes through the filterless device providing personal protection against the Coronavirus (COVID-19.
  • "\nThanks to its patented filterless Plascide plasma technology, airKAVE works like no other air purification system on the market destroying microorganisms at the molecular level.
  • With airKAVE, air is pulled into the internal Plascide reactor, creating a thunderstorm of micro-lightning plasma which puts the microscopic particles into an electrified state at room temperature.

NuWave Voluntarily Modifies Certain OxyPure Air Purifier Claims Following National Advertising Division Inquiry into Implied COVID-19 Messages

Retrieved on: 
Tuesday, April 13, 2021
Sarbecovirus, Zoonoses, Animal diseases, Medical specialties, Children's Advertising Review Unit, NuWave, Severe acute respiratory syndrome, Coronavir

Sleeping problems are epidemic and carry their own health risks.

Key Points: 
  • Sleeping problems are epidemic and carry their own health risks.
  • However, it agreed to modify its website advertising to state: "OxyPure is Calculated to Remove 99.999% of Coronavirus Surrogate from the Air in Areas up to 1,200 Square Feet in 6 Hours!
  • * which is qualified by a clear and conspicuous disclosure directly underneath the claim, stating that "SARS-COV-2 was not used in the study conducted by the University of Minnesota for the efficacy of NuWave OxyPure.
  • For full text of NAD, NARB, and CARU decisions, subscribe to the online archive .\nAbout BBB National Programs:BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard.

Innovation Pharma Announces Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology’s Annual Meeting

Retrieved on: 
Wednesday, April 7, 2021
Antiviral drugs, Virology, Medical specialties, Microbiology, Coronavirus, Coronavir, Severe acute respiratory syndrome coronavirus, Broad-spectrum antiviral drug, Novel coronavirus, COVID-19, Severe acute respiratory syndrome–related coronavirus

Brilacidin was shown to exhibit a potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, as well as different types of alphaviruses, in cell culture.

Key Points: 
  • Brilacidin was shown to exhibit a potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, as well as different types of alphaviruses, in cell culture.
  • Further details on the Brilacidin ASV 2021 presentation will be forthcoming.
  • An effective broad-spectrum antiviral is largely absent in medicine today, commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.
  • So it is extremely rewarding to see Brilacidin exhibit consistent in vitro inhibition against coronaviruses and alphaviruses.

Metrex Surface Disinfectant Portfolio Secures EPA Approval for Use Against SARS-CoV-2 Virus

Retrieved on: 
Monday, April 5, 2021
Medical Supplies, Retail, Health, Other Retail, Infectious diseases, Home Goods, Specialty, Coronaviridae, Sarbecovirus, Medical specialties, Health sciences, Bat virome, Zoonoses, Animal virology, Severe acute respiratory syndrome, COVID-19, Coronavirus, Coronavir, Disinfectant

The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex , as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.

Key Points: 
  • The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex , as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.
  • View the full release here: https://www.businesswire.com/news/home/20210405005058/en/
    The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex, as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.
  • The below Metrex surface disinfection products are effective against SARS-CoV-2, helping to give front-line workers peace of mind that our products are protecting their patients and themselves.
  • The following Metrex products have been approved by the EPA for efficacy against SARS-CoV-2 and are on the EPA list N for use against SARS-CoV-2:

Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement

Retrieved on: 
Thursday, April 1, 2021
Antiviral drugs, Sarbecovirus, Medical specialties, Arbutus Biopharma, Medicine, ABUS, Virology, Mpro, Coronavirus, Coronavir, Severe acute respiratory syndrome, 3C-like protease

and MUNICH, Germany, April 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ: ABUS), X-Chem, Inc. (X-Chem) and Proteros biostructures GmbH (Proteros) announced today that they have entered into a discovery research and license agreement focused on the discovery of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease (Mpro).

Key Points: 
  • and MUNICH, Germany, April 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ: ABUS), X-Chem, Inc. (X-Chem) and Proteros biostructures GmbH (Proteros) announced today that they have entered into a discovery research and license agreement focused on the discovery of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease (Mpro).
  • The agreement is designed to accelerate the development of pan-coronavirus agents to treat COVID-19 and potential future coronavirus outbreaks.
  • We are exhilarated to join forces with industry leaders Arbutus and Proteros in this effort and bring our drug discovery expertise to this important area of antiviral research.
  • Arbutus is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection.